AUS
NZ
UK
CA
USA
IND
Headlines:
- Clariant Reports Q2 EBITDA Decline but Improves Adjusted Metrics
- Sales Dip in Q2, But Regional Performance and Pricing Trends Show Mixed Results
- FY24 Outlook Upgraded with Higher EBITDA Margin Forecast and Stable Sales Growth
Specialty chemicals enterprise Clariant AG (CLZNY.PK) disclosed on Tuesday that its second-quarter Group EBITDA experienced a decrease of 5 percent, totalling 166 million Swiss francs, compared to 175 million francs recorded in the same period last year. This drop led to a reduction in the EBITDA margin, which fell to 15.7 percent from 16.1 percent in the prior year. Despite this decline, the adjusted EBITDA saw a notable increase, reaching 164 million francs, which represents a 21 percent rise from 135 million francs a year ago. This improvement led to an adjusted EBITDA margin enhancement to 15.5 percent from 12.5 percent previously. In terms of sales performance, Clariant reported a 3 percent decline for the second quarter, with total sales amounting to 1.056 billion francs, down from 1.084 billion francs in the prior year.
The organic sales growth, measured in local currencies, fell by 3 percent. The company observed growth in segments such as Care Chemicals and Adsorbents & Additives; however, this was counterbalanced by an anticipated decrease in Catalysts. Although the volume of sales remained stable, the pricing aspect experienced a 3 percent year-on-year decline. Notably, while the overall performance was impacted, Clariant's focus on consumer stocks like Care Chemicals indicates a strategic positioning to capitalize on resilient market segments.
Geographically, the sales performance showed varied results. In the Europe, Middle East, and Africa region, sales remained steady on an organic basis, while the Americas experienced a 1 percent organic decline.
Looking forward to the fiscal year 2024, Clariant has adjusted its sales growth forecast. The company now anticipates a flat to low single-digit percentage increase in sales, an upgrade from the earlier expectation of a low single-digit percentage growth. This revised outlook is supported by anticipated growth in the Care Chemicals sector, particularly due to the integration of Lucas Meyer Cosmetics, and in the Adsorbents & Additives segment. This expected growth is projected to counterbalance uncertainties related to the recovery phase of Catalysts in the latter half of the year. Additionally, Clariant has increased its reported EBITDA margin forecast to approximately 16 percent, a 100 basis point improvement from the earlier estimate of around 15 percent. This revision includes the positive effects from the Lucas Meyer Cosmetics acquisition, which is advancing as anticipated.
Looking further ahead to 2025, Clariant maintains its expectation for a significant recovery in profitability. Based on an anticipated improvement of 3 percent to 5 percent in key end-market demand, the company projects an EBITDA margin ranging between 17 percent and 18 percent for 2025.
